Cargando…
Phase I study of intraperitoneal bevacizumab for treating refractory malignant ascites
OBJECTIVE: This prospective, dose-escalation phase I study evaluated the safety and efficacy of intraperitoneal bevacizumab in managing refractory malignant ascites and explored the recommended dose of bevacizumab for further study. METHODS: Patients with refractory malignant ascites were enrolled....
Autores principales: | Kou, Furong, Gong, Jifang, Li, Yan, Li, Jian, Zhang, Xiaotian, Li, Jie, Shen, Lin |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7903826/ https://www.ncbi.nlm.nih.gov/pubmed/33616416 http://dx.doi.org/10.1177/0300060520986664 |
Ejemplares similares
-
Role of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer
por: Xie, Tian-Yu, et al.
Publicado: (2020) -
Pyrotinib alone or in combination with docetaxel in refractory HER2‐positive gastric cancer: A dose‐escalation phase I study
por: Liu, Dan, et al.
Publicado: (2023) -
Intraperitoneal ziv-aflibercept effectively manages refractory ascites in colorectal cancer patients
por: Lu, Chieh-Sheng, et al.
Publicado: (2016) -
Efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in the management of malignant ascites
por: Jiao, Jie, et al.
Publicado: (2020) -
Current management of refractory ascites in patients with cirrhosis
por: Zhao, Ruihong, et al.
Publicado: (2017)